- NSE
ONESOURCE SPECIALTY PHARMA LTD
Healthcare ONESOURCE
1194.50INR
80.50
(
7.23%)
Last update at 2026-01-30 15:59:30
Day Range
52 Week Range
Fundamentals
- Previous Close 1114.00
- Market Cap 203986.14M
- Volume560,756
- P/E Ratio 501.41
- EBITDA 4896.01M
- Revenue TTM 15215.49M
- Revenue Per Share TTM 134.06
- Gross Profit TTM 10411.77M
- Diluted EPS TTM 3.55
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Financials
Income Statement
Balance Sheet
Change in Cash
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Income before tax | -670.66M | -3656.97M | -4156.45M |
| Net income | -179.71M | -3911.65M | -7998.30M |
| Total Revenue | 14448.53M | 1719.19M | 387.14M |
| Gross Profit | 10098.19M | 1014.10M | 183.03M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 |
| Total assets | 75502.42M | 13086.11M | 20088.08M |
| Intangible assets | 15506.74M | 3254.46M | 3377.06M |
| Other current assets | 1704.11M | - | - |
| Deferred long term liab | - | - | - |
| Non current assets other | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 |
| Change in Cash | 1430.73M | 127.90M | -1122.81M |
| Operating Cash | -678.54M | -1072.11M | -1627.65M |
| Free Cash Flow | -1960.02M | -1709.78M | -2067.60M |
Peer Comparison
Sector: Healthcare Industry: Biotechnology
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| ONESOURCE ONESOURCE SPECIALTY PHARMA LTD |
80.50 7.23% | 1194.50 | 203986.14 | 501.41 |
| BIOCON Biocon Limited |
-3.90 -1.05% | 368.40 | 569444.73 | 94.72 |
| ANTHEM Anthem Biosciences Ltd |
-0.65 -0.11% | 606.75 | 416096.85 | 91.92 |
| CONCORDBIO Concord Biotech Limited |
19.10 1.64% | 1183.20 | 140309.66 | 43.31 |
| BLUEJET Blue Jet Healthcare Limited |
-8.30 -1.97% | 413.00 | 89232.91 | 25.36 |
Profile
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
ONESOURCE SPECIALTY PHARMA LTD
Star 1, Opp IIM Bangalore, Bengaluru, India, 560076
- 91 80 6784 0738
- https://www.onesourcecdmo.com
- Employees : 1,412
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Neeraj Sharma | CEO, MD & Director | 1972 |
| Mr. Anurag Bhagania | Chief Financial Officer | 1972 |
| Ms. Allada Trisha | Company Secretary & Compliance officer | NA |
| Mr. Arun Kumar Pillai B.Com. | Founder & Non-Executive Director | 1961 |
| Mr. Biju Mathew | Chief Operating Officer | NA |
| Dr. Prateek Gupta | Senior VP & Head of Technical Development | NA |
| Mr. Milan Doshi | Senior Vice President of Global BD | NA |
| Mr. Ravi Kumar | Head of Corporate Strategy & Operational Excellence | NA |
| Mr. Bernhard Thurnbauer | Chief Quality Officer | NA |
| Mr. Jeffrey Wong | Chief Business Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.